Clustered Distribution of Natural Product Leads of Drugs in the Chemical Space as Influenced by the Privileged Target-Sites

Lin, Tao; Zhu, Feng; Chu, Qing; Zhang, Cheng; Chen, Shangying; Zhang, Peng; Zhang, Cunlong; Tan, Chunyan; Gao, Chunmei; Chen, Zhe; Jiang, Yuyang; Chen, Yu Zong

doi:10.1038/srep09325

Cited by 22 publications

(19 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following the assumption that plant-derived chemicals are constrained to evolutionary plant lineages 4 5 6 , phylogeny-guided approaches have been seen as one of the time-efficient and informed approaches to plant-based drug discovery 7 8 9 10 11 12 13 14 . Some of these approaches utilise information from ethnomedicine: the use of plants by humans as medicines 15 .…”

mentioning

confidence: 99%

Evolutionary prediction of medicinal properties in the genus Euphorbia L.

Ernst

Saslis‐Lagoudakis

Grace

et al. 2016

Sci Rep

View full text Add to dashboard Cite

The current decrease of new drugs brought to the market has fostered renewed interest in plant-based drug discovery. Given the alarming rate of biodiversity loss, systematic methodologies in finding new plant-derived drugs are urgently needed. Medicinal uses of plants were proposed as proxy for bioactivity, and phylogenetic patterns in medicinal plant uses have suggested that phylogeny can be used as predictive tool. However, the common practice of grouping medicinal plant uses into standardised categories may restrict the relevance of phylogenetic predictions. Standardised categories are mostly associated to systems of the human body and only poorly reflect biological responses to the treatment. Here we show that medicinal plant uses interpreted from a perspective of a biological response can reveal different phylogenetic patterns of presumed underlying bioactivity compared to standardised methods of medicinal plant use classification. In the cosmopolitan and pharmaceutically highly relevant genus Euphorbia L., identifying plant uses modulating the inflammatory response highlighted a greater phylogenetic diversity and number of potentially promising species than standardised categories. Our interpretation of medicinal plant uses may therefore allow for a more targeted approach for future phylogeny-guided drug discovery at an early screening stage, which will likely result in higher discovery rates of novel chemistry with functional biological activity.

show abstract

mentioning

confidence: 99%

Evolutionary prediction of medicinal properties in the genus Euphorbia L.

Ernst

Saslis‐Lagoudakis

Grace

et al. 2016

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Although very few natural product‐derived drugs originating from marine organisms are currently approved, mining the marine environment will pave the way for biological and chemical novelties . The ocean provides extreme growth conditions for organisms, such as high pressure, high salinity, low (or high) temperature, limited sunlight, low nutrient concentration, and low oxygen content .…”

Section: Novel Organisms and Manipulation Of Natural Metabolismmentioning

confidence: 99%

“…Although very few natural product-derived drugs originating from marine organisms are currently approved, mining the marine environment will pave the way for biological and chemical novelties. 46,47,106 The ocean provides extreme growth conditions for organisms, such as high pressure, high salinity, low (or high) temperature, limited sunlight, low nutrient concentration, and low oxygen content. 107 Under these physically variable and competitive environments, many branches of life are complex and exclusively marine, 46 and certain marine ecosystems possess much higher chemical diversity than what is described terrestrially, making them a unique and rich resource of diverse compounds.…”

Section: Marine Organismsmentioning

confidence: 99%

Strategies to diversify natural products for drug discovery

Lou

2017

Medicinal Research Reviews

222

130

View full text Add to dashboard Cite

Natural product libraries contain specialized metabolites derived from plants, animals, and microorganisms that play a pivotal role in drug discovery due to their immense structural diversity and wide variety of biological activities. The strategies to greatly extend natural product scaffolds through available biological and chemical approaches offer unique opportunities to access a new series of natural product analogues, enabling the construction of diverse natural product-like libraries. The affordability of these structurally diverse molecules has been a crucial step in accelerating drug discovery. This review provides an overview of various approaches to exploit the diversity of compounds for natural product-based drug development, drawing upon a series of examples to illustrate each strategy.

show abstract

“…More than 20,000 new natural marine products have been isolated over the past 50 years of which 71% have not been found on land 203 . These substances are abundant, covering almost all pharmaceutical fields 204 . The basic structure of bioactive substances discovered from marine organisms is primarily peptides (or proteins), but polysaccharides (including glucoside), lipids and small molecules have also been found, with activities such as antibacterial, antitumor, antiviral, cytotoxic, anticoagulant, and antihypertensive.…”

Section: Marine Natural Productsmentioning

confidence: 99%

The Report of Marine Life Genomic Research

Fan¹,

Chen²,

Jin³

et al. 2018

Preprint

View full text Add to dashboard Cite

With the continuing development of sequencing technology, genomics has been applied in a variety of biological research areas. In particular, the application of genomics to marine species, which boast a high diversity, promises great scientific and industrial potential. Significant progress has been made in marine genomics especially over the past few years. Consequently, BGI, leveraging its prominent contributions in genomics research, established BGI-Qingdao, an institute specifically aimed at exploring marine genomics. In order to accelerate marine genomics research and related applications, BGI-Qingdao initiated the International Conference on Genomics of the Ocean (ICG-Ocean) to develop international collaborations and establish a focused and coherent global research plan. Last year, the first ICG-Ocean conference was held in Qingdao, China, during which 47 scientists in marine genomics from all over the world reported on their research progress to an audience of about 300 attendees. This year, we would like to build on that success, drafting a report on marine genomics to draw global attention to marine genomics. We summarized the recent progress, proposed future directions, and we would like to enable additional profound insights on marine genomics. Similar to the annual report on plant and fungal research by Kew Gardens, and the White Paper of ethical issues on experimental animals, we hope our first report on marine genomics can provide some useful insights for researchers, funding agencies as well as industry, and that future versions will expand upon the foundation established here in both breadth and depth of knowledge.This report summarizes the recent progress in marine genomics in six parts including: marine microorganisms, marine fungi, marine algae and plants, marine invertebrates, marine vertebrates and genomics-based applications.

show abstract

Clustered Distribution of Natural Product Leads of Drugs in the Chemical Space as Influenced by the Privileged Target-Sites

Cited by 22 publications

References 67 publications

Evolutionary prediction of medicinal properties in the genus Euphorbia L.

Evolutionary prediction of medicinal properties in the genus Euphorbia L.

Strategies to diversify natural products for drug discovery

The Report of Marine Life Genomic Research

Contact Info

Product

Resources

About